Ginkgo Bioworks Inc. (DNA)
5.67
-0.03 (-0.53%)
At close: Apr 01, 2025, 3:59 PM
5.49
-3.17%
After-hours: Apr 01, 2025, 08:00 PM EDT
-0.53% (1D)
| Bid | 5.23 |
| Market Cap | 329.05M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -10.54 |
| PE Ratio (ttm) | -0.54 |
| Forward PE | -1.54 |
| Analyst | Sell |
| Ask | 5.75 |
| Volume | 1,296,112 |
| Avg. Volume (20D) | 1,659,058 |
| Open | 5.69 |
| Previous Close | 5.70 |
| Day's Range | 5.48 - 5.88 |
| 52-Week Range | 5.26 - 47.60 |
| Beta | 1.24 |
About DNA
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Bi...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 19, 2021
Employees 834
Stock Exchange NYSE
Ticker Symbol DNA
Website https://www.ginkgobioworks.com
Analyst Forecast
According to 5 analyst ratings, the average rating for DNA stock is "Sell." The 12-month stock price forecast is $10, which is an increase of 76.37% from the latest price.
Stock Forecasts1 month ago
-11.47%
Ginkgo Bioworks Holdings shares are trading lower ...
Unlock content with
Pro Subscription
4 months ago
-4.22%
Ginkgo Bioworks shares are trading higher after the company reported better-than-expected Q3 EPS and sales and raised its FY24 revenue guidance.
